Vagus nerve stimulation for refractory epilepsy in children

Interventional procedures guidance
Published: 24 March 2004
www.nice.org.uk/guidance/ipg50

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

1 Guidance

1.1 Current evidence on the safety and efficacy of vagus nerve stimulation for
refractory epilepsy in children appears adequate to support the use of this procedure, provided that the normal arrangements are in place for consent, audit and clinical governance.

1.2 The procedure should only be undertaken by specialist paediatric epilepsy teams.

1.3 Almost all the current evidence on the efficacy of the procedure relates to reducing seizure frequency only. However the effect on quality of life remains uncertain. Future audit and research should include quality of life measures. Patients, carers and children should be informed about the unpredictability of benefit. Use of the Institute's information for the public is recommended.

2 The procedure

2.1 Indications

2.1.1 Vagus nerve stimulation is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients who are refractory to anti-epileptic medication. This includes patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalisation) or generalised seizures.

2.2 Outline of the procedure

2.2.1 A battery-powered pulse-generating device is implanted under the skin of the upper left chest. A wire is tunnelled under the skin and connected to the left vagus nerve in the neck. The stimulation parameters (pulse width and frequency, current intensity, and on/off cycles) are programmed into the pulse generator via a programming wand. Patients or carers can give additional stimulation or temporarily inhibit stimulation. The battery lasts 8–10 years and can be replaced under local anaesthesia. A typical treatment regimen might comprise intermittent stimulation for 30 seconds every 5 minutes throughout the day and night.

2.3 Efficacy

2.3.1 In one study of 50 children aged 12 years and younger, 23 (46%) experienced a
greater than 50% reduction in seizure frequency. In a study of 28 children aged 12 years and younger, a mean reduction of 62% in seizure frequency was reported at 1 year. There was some evidence to suggest that quality of life improved following the procedure. Comparisons are difficult to make between the studies because of variations in the patient populations, the methods of outcome assessment and the reporting of outcomes. For more details, refer to the Sources of evidence section.

2.3.2 The Specialist Advisors also noted that the procedure seemed to have some benefits in terms of mood and quality of life.

2.4 Safety

2.4.1 The most commonly reported complications were hoarseness, sore throat and cough. In a case series of 125 children, 73 children (58%) experienced voice alteration and 48 children (38%) experienced coughing during stimulation. More serious adverse events included infection (requiring device removal) in 3% (3/100) to 6% (1/16) of patients, and breathing irregularities in 19% (3/16) of patients. For more details, refer to the Sources of evidence section.

2.4.2 The Specialist Advisors believed that this is a safe procedure with no major complications.

3 Further information

3.1 The Institute is in the process of developing a clinical guideline on epilepsy. The expected date of issue is June 2004 [Now published as 'The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care'].

Andrew Dillon
Chief Executive
March 2004

Sources of evidence

The evidence considered by the Interventional Procedures Advisory Committee is described in the following document.
Information for patients

NICE has produced information on this procedure for patients and carers. It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.

4 About this guidance

NICE interventional procedure guidance makes recommendations on the safety and efficacy of the procedure. It does not cover whether or not the NHS should fund a procedure. Funding decisions are taken by local NHS bodies after considering the clinical effectiveness of the procedure and whether it represents value for money for the NHS. It is for healthcare professionals and people using the NHS in England, Wales, Scotland and Northern Ireland, and is endorsed by Healthcare Improvement Scotland for implementation by NHSScotland.

This guidance was developed using the NICE interventional procedure guidance process.

It has been incorporated into the NICE pathway on epilepsy, along with other related guidance and products.

We have produced a summary of this guidance for patients and carers. Information about the evidence it is based on is also available.

Changes since publication

28 January 2012: minor maintenance.

Your responsibility

This guidance represents the views of NICE and was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers.
Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

Copyright

© National Institute for Health and Clinical Excellence 2004. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

Contact NICE

National Institute for Health and Clinical Excellence
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

www.nice.org.uk
nice@nice.org.uk
0845 033 7780

Endorsing organisation

This guidance has been endorsed by Healthcare Improvement Scotland.